Similar to the synergistic anti-tumor activity of IL-4 cytotoxin and gemcitabine, the combination of IL-13 cytotoxin with gemcitabine exhibited a remarkable and specific anti-tumor impact in pancreatic cancer cells and advanced pancreatic cancer animal models [116]. This evidence concerns the gene IL4 and familial pancreatic carcinoma.